Animal study · mice
Vesugen (KED) prevented dendritic spine loss in Alzheimer's mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
This adds early mouse evidence that Vesugen may help protect nerve connections in an Alzheimer's model, but it does not show any benefit in humans.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2021
- Journal
- Pharmaceuticals (Basel)
What they tested
The team tested whether the KED and EDR peptides protect nerve connections in a mouse model of Alzheimer's disease, and looked for possible molecular reasons.
How the study was done
A study in 5xFAD mice, an Alzheimer's disease mouse model, given daily KED peptide injections into the belly cavity from 2 to 4 months of age at 400 μg/kg. The team also used computer molecular modeling and docking to see how the peptides might bind DNA.

What they found
In 5xFAD mice, daily KED at 400 μg/kg tended to increase neuroplasticity, the brain's ability to change its connections. Both KED and EDR prevented the loss of dendritic spines, small bumps on nerve cells where connections form, in 5xFAD-M mice. In the computer modeling, the peptides' lowest-energy complexes with DNA settled on similar DNA sequences. EDR had predicted binding sites near genes linked to Alzheimer's disease, including APOE, CASP3 and SOD2.
What it doesn’t show
This was work in mice and in computer models, not a result in people, and the neuroplasticity effect was only a trend. The gene binding sites were predicted by modeling for EDR, not measured for KED.
The paper
Khavinson et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021.
The compound
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.